Humacyte Q2 2026 Earnings Report

Humacyte EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.10
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Humacyte Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $1.12 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Humacyte Announcement Details

• Quarter: Q2 2026
• Date: 8/10/2026
• Time: Before Market Opens
• Conference Call Date: Friday, August 14, 2026
• Conference Call Time: 12:30PM ET

Humacyte (NASDAQ:HUMA) is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation. Humacyte is also exploring additional indications, including peripheral and coronary artery bypass and central venous access, with the goal of addressing significant unmet medical needs in cardiovascular surgery and interventional medicine. Research and development efforts are supported by Good Manufacturing Practice (GMP) facilities in the United States, enabling scale-up from laboratory to commercial production.

Founded in 2004 by Dr. Scott B. Rhodes at Duke University, Humacyte is headquartered in Durham, North Carolina, with ongoing clinical programs and partnerships extending into Europe and North America. The company is led by a management team with experience spanning cell therapy, regenerative medicine and vascular surgery. Humacyte continues to work alongside clinical investigators and strategic collaborators to advance its HAV technology toward regulatory approval and broad clinical adoption.